GlassScriptPhysician profile
Manoj Bs Wunnava
NPI 1720263239
$1,111.75
in general payments reported to CMS, 2019-2025
14 companies · $89.10 in 2025
The $89.10 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $101 · 2021: $67.11 · 2022: $67.50 · 2023: $346 · 2024: $255 · 2025: $89.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.36 | 2019-2025 | Relistor |
| Abbott Laboratories | $145.42 | 2021-2024 | Eterna |
| Nevro Corp. | $138.43 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $124.81 | 2023 | Spravato |
| Collegium Pharmaceutical, INC. | $115.99 | 2023-2024 | Belbuca, Xtampza |
| Virtus Pharmaceuticals LLC | $91.75 | 2023-2025 | Levorphanol Tartrate |
| Medtronic, INC. | $67.50 | 2022 | |
| Pfizer INC. | $62.92 | 2019-2024 | |
| Biodelivery Sciences International, INC. | $42.07 | 2019-2021 | |
| Abbvie INC. | $37.74 | 2019-2020 | |
| Valinor Pharma, LLC | $30.07 | 2024-2025 | Movantik |
| Protega Pharmaceutials INC | $16.26 | 2024 | Roxybond |
| Amgen INC. | $14.32 | 2019 | |
| Grifols USA, LLC | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoj Wunnava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.